ArticleEClinicalMedicine2025
A post-diagnostic psycho-education, acceptance and commitment therapy programme for caregivers of children recently diagnosed with autism: a randomised controlled trial-based cost-effectiveness analysis (REACH-ASD Trial).
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Caregivers of autistic children experience higher rates of mental health difficulties, caregiving complexities, and employment challenges, resulting in reduced health status and productivity losses. We evaluated the cost-effectiveness of a group psychosocial intervention (Empower-Autism) plus treatment as usual (TAU), in comparison to TAU alone, for caregivers of children recently diagnosed with ASD. Methods: A multicentre, assessor-masked, randomised controlled trial of 379 primary caregivers of children with a recent ASD diagnosis in North-West England prospectively collected economic data. The trial (ISRCTN 45412843) was prospectively registered on Sept 11, 2019 and participants were referred and screened for inclusion between Sept 16, 2020 and April 14, 2022. The final data extract was performed on Aug 31, 2023. The primary outcome of the cost-effectiveness analysis was quality-adjusted life years (QALYs) at 52-week follow-up. Missing data were imputed using multiple imputation. Uncertainty was explored by probabilistic bootstrapping. Sensitivity analyses tested the impact of study design and assumptions on the incremental cost-effectiveness ratio (ICER). Findings: Primary (imputed data) and complete case analyses have contrasting results; the complete case suggests the intervention may be cost-effective (net cost £786; net QALY 0.049; ICER ∼£16 k) in contrast to the primary analysis (net cost £756; net QALY 0.015; ICER ∼£51 k). Using the GHQ-30 (trial primary outcome, measuring mental health) as an alternative measure of benefit resulted in a cost of £150 per point improvement (statistically significant health gain, clinically meaningful at ∼£750/individual). Interpretation: The proportion of participants with incomplete data, likely in part due to the COVID-19 pandemic, results in uncertainty. However, there is some indication that the intervention is cost-effective. Further research is needed to explore the potential longer-term cost-effectiveness of Empower-Autism. Funding: NIHRHTA Programme (17/80/09).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.